ArticleJournal of dental sciences2026
Camphorquinone-induced phospholipase A
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Camphorquinone (CQ) is a widely-used photo-initiator in dentin bonding agent (DBA) and composite resin to promote resin polymerization and restore tooth decay. CQ may potentially induce pulpal inflammation and affect viability of dental pulp especially when the remaining dentin is minimal. Phospholipase A2 (PLA2) and cyclooxygenase-2 (COX-2) are crucial enzymes for tissue inflammation by inducing prostaglandins' production. However, little is known about the PLA2 isoforms' expression and their response to CQ in the dental pulp. Materials and methods: Human dental pulp cells (HDPCs) were exposed to various concentrations of CQ with/without inhibitors (aspirin, eugenol or ASB14780) for 24 h. Protein and mRNA expression of cyclooxygenase-2 (COX-2), cPLA2, sPLA2 and iPLA2 were investigated by immunofluorescent staining and real-time PCR, respectively. Culture medium was collected for analysis of 8-isoprostane and PGE Results: CQ regulated the mRNA and protein expression of COX-2, cPLA2, sPLA2 and iPLA2 at concentrations of 2 and 3 mM. Aspirin, eugenol and ASB14780 (a PLA2 inhibitor) differentially attenuated the CQ-induced PGE Conclusion: CQ may possibly stimulate pulpal inflammation and necrosis by induction of cytotoxicity, 8-isoprostane and PGE2 production that are differentially regulated by various PLA2s. Aspirin, eugenol and PLA2 inhibitors may have potential therapeutic use to control pulpal inflammation after composite resin restoration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.